For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

CCTG Investigator Network

National and International

CCTG is an academic cooperative group that unites the efforts of investigators at many different universities, hospitals, and cancer care centres across Canada and across the globe. Any particular member of our network might have direct access to just a handful of patients who would be suitable for testing some new drug or other therapy; however, collaboration across the group ensures the possibility of a trial with a sufficiently large number of participants to make for a scientifically significant research undertaking.

The bulk of the support work to conduct a clinical trial is facilitated by CCTG, the central office coordinates the activities of approximately 2,100 investigators, including oncologists, hematologists, radiologists, surgeons, and nurses at more than 85 member institutions across the country. At any given time, we are working together on over 40 trials across Canada, and in collaboration with similar groups around the world.

Collectively the network brings together the knowledge, the skills, and the infrastructure to perform definitive clinical trials that has and will continue to change medical practice.

"I don’t think you could identify any cancer specialist in the country who has not participated in one of our clinical trials. This fact alone is recognition that you can derive benefit by being collaborative and partnering, and clinical trials are, by necessity, the most collaborative of research activities." - Dr. Janet Dancey, Director, CCTG.

Find out more about the clinical trail research leadership working with CCTG

CCTG network scientists have earned a reputation for changing cancer treatment practices around the world. Part of their secret is that they ask the right questions and take a scientific approach to find the right answers, listen to some of the innovative investigators in the network discuss their trials:

Dr. Rebecca Auer is a surgical oncologist and translational researcher at the Ottawa Hospital. Dr. Daniel Renouf is a medical oncologist at the British Columbia Cancer Agency. Dr. Sharlene Gill is a medical oncologist at the BC Cancer Agency


Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition

Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition.

More >>
An interview with Senior Investigator Annette Hay

An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.

More >>

Pregnancy and the safety of Interrupting therapy for young women with breast cancer

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy.

More >>